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REESE ET AL 2063Background: Epigenetic mechanisms, including methylation,
can contribute to childhood asthma. Identifying DNA
methylation profiles in asthmatic patients can inform disease
pathogenesis.
Objective: We sought to identify differential DNA methylation
in newborns and children related to childhood asthma.
Methods: Within the Pregnancy And Childhood Epigenetics
consortium, we performed epigenome-wide meta-analyses of
school-age asthma in relation to CpG methylation
(Illumina450K) in blood measured either in newborns, in
prospective analyses, or cross-sectionally in school-aged
children. We also identified differentially methylated regions.
Results: In newborns (8 cohorts, 668 cases), 9 CpGs (and 35
regions) were differentially methylated (epigenome-wide
significance, false discovery rate < 0.05) in relation to asthma
development. In a cross-sectional meta-analysis of asthma and
methylation in children (9 cohorts, 631 cases), we identified 179
CpGs (false discovery rate < 0.05) and 36 differentially
methylated regions. In replication studies of methylation in
other tissues, most of the 179 CpGs discovered in blood
replicated, despite smaller sample sizes, in studies of nasal
respiratory epithelium or eosinophils. Pathway analyses
highlighted enrichment for asthma-relevant immune processes
and overlap in pathways enriched both in newborns and
children. Gene expression correlated with methylation at most
loci. Functional annotation supports a regulatory effect on gene
expression at many asthma-associated CpGs. Several implicated
genes are targets for approved or experimental drugs, including
IL5RA and KCNH2.
Conclusion: Novel loci differentially methylated in newborns
represent potential biomarkers of risk of asthma by school age.
Cross-sectional associations in children can reflect both risk for
and effects of disease. Asthma-related differential methylation
in blood in children was substantially replicated in eosinophils
and respiratory epithelium. (J Allergy Clin Immunol
2019;143:2062-74.)
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the underlying mechanisms remain poorly understood. Genome-
wide association study (GWAS) meta-analyses have identified
many loci related to asthma,2 but these explain only a modest pro-
portion of variation in asthma risk.3 Increasing evidence suggests
that epigenetic variation can play a role in asthma pathogenesis.4
DNA methylation is the most studied epigenetic modification in
human subjects. Prospective examination of methylation patterns
in newborns in relation to asthma development might identify
genes and mechanisms involved in the developmental origins of
asthma.5
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2064 REESE ET AL16-149)6-12 have identified differential methylation at some spe-
cific gene regions. The only meta-analysis of epigenome-wide
methylation in childhood asthma included 392 cases but did not
examine newborn methylation.13 A larger meta-analysis,
including both methylation in newborns and at later ages, would
increase the power for identification of novel loci.
Using the Illumina HumanMethylation450K BeadChip
(Illumina450K; Illumina, San Diego, Calif), we performed a
large-scale meta-analysis of childhood asthma in relation to
whole-blood DNA methylation in newborns to evaluate whether
methylation patterns at birth relate to disease development. We
separately examined cross-sectional associations between whole-
blood DNAmethylation and the presence of asthma in children of
at least school age. We investigated the association of DNA
methylation in blood and asthma at both individual sites and over
genomic regions and evaluated the potential functional effect of
findings by integrating gene expression, pathway analyses,
detailed functional annotation, and the search for druggable
targets of differentially methylated loci. We also followed up our
findings using methylation data in eosinophils and from nasal
respiratory epithelium.METHODS
The Methods section in this article’s Online Repository at www.jacionline.
org provides additional details on the methods used in this study.Study population
The Pregnancy and Childhood Epigenetics (PACE) consortium is an
international consortium of cohorts with Illumina450KDNAmethylation data
at birth (newborns) or in childhood.14 In prospective analyses we evaluated
childhood asthma at school age in relation to blood DNA methylation data
from newborns (8 cohorts: Avon Longitudinal Study of Parents and Children
[ALSPAC], Children’s Health Study [CHS], Etude des Determinants pre et
post natals du developpement et de la sante de l9Enfant [EDEN] birth cohort,
Generation R, Genetics of Overweight Young Adults [GOYA], Norwegian
Mother and Child [MoBa] cohort 1, MoBa2, and Newborn Epigenetics STudy
[NEST]). We also conducted cross-sectional analyses of methylation
measured in children in relation to asthma status at that same time point (9 co-
horts: Children, Allergy, Milieu, Stockholm, Epidemiology [BAMSE] Epi-
Gene; BAMSE MeDALL; European Childhood Obesity Project [CHOP];
Genes-environments & Admixture in Latino Americans [GALA II]; Inner
City Asthma Consortium [ICAC]; Northern Finland Birth Cohort [NFBC]
1986; Prevention and Incidence of Asthma and Mite Allergy [PIAMA]; the
Raine study; and Swedish Twin studyOn Prediction and Prevention of Asthma
[STOPPA]). To avoid problems from small numbers, we set a minimum of 15
cases for participating cohorts to perform analyses.Harmonization of childhood asthma variables
We developed a harmonized definition of asthma based on the question-
naire data available in each cohort. Asthma was assessed at school age, which
was defined as 5 years or older, and varied by cohort. Asthmawas defined by a
doctor’s diagnosis of asthma and the report of at least 1 of the following: (1)
current asthma, (2) asthma in the past year, or (3) asthmamedication use in the
last year. Noncases were children who had never had asthma.Methylation data measurement and quality control
DNA methylation was measured with the Illumina450K platform. Cohorts
performed their own quality control, normalization, and analysis of untrans-
formed b values. Previously, we found that the use of different preprocessing
or normalization methods did not influence meta-analysis results.15,16 Probes
on the X and Y chromosomes were removed, as were those in which a singlenucleotide polymorphism (SNP) was present in the last 5 bp of the probe,
which could interfere with binding. Rather than remove probes a priori that
have appeared on various published lists of potentially cross-reactive probes
or probes near SNPs, we examined post hoc those that appear in statistically
significant results.17,18
Annotation of CpGs
This article’s tables include theUniversity ofCalifornia, SantaCruz (UCSC)
RefGene name from Illumina’s annotation file and enhanced annotation to the
UCSC KnownGene. UCSC KnownGene annotations include the nearest gene
within 10Mbof eachCpGandfill inmanymissing gene names.All annotations
use the human February 2009 (GRCh37/hg19) assembly.Cohort-specific statistical analyses
The association of methylation and asthma was assessed by using logistic
regression. Covariates included in adjusted models were maternal age,
sustained maternal smoking during pregnancy,15 maternal asthma, socioeco-
nomic status, and child’s sex. Cohorts adjusted for batch effects by using Com-
Bat19 or SVA20 or by including a batch covariate in their models. We also
adjusted for potential cell-type confounding by including estimated propor-
tions calculated by using the Housemanmethod,21 with a cord blood reference
panel22 for newborn cohorts or an adult blood reference panel23 for child co-
horts. The primary models presented include adjustment for covariates and
cell type; reduced models are presented for comparison.Meta-analyses
As in other consortium genomic analyses,24,25 wemeta-analyzed the study-
specific results using inverse variance weighting, which is also referred to as
fixed-effects meta-analysis, with METAL.26 We accounted for multiple
testing by controlling for the false discovery rate (FDR) at 0.05.27 To enable
readers to assess whether the results across studies are consistent, we provide
forest plots of the study-specific effect estimates and 95%CIs. As another way
to visualize meaningful heterogeneity or influential results, we also provide
plots for all significant CpGs of regression coefficients and 95% CIs where
we leave out 1 cohort at a time. Although inverse variance–weighted meta-
analysis does not require the assumption of homogeneity,25 where there is
even nominal evidence for heterogeneity (Pheterogeneity < .05without correction
for multiple testing) for any CpG we report as genome-wide significant, we
also provide meta-analysis P values from standard random-effects meta-anal-
ysis by using METASOFT.28Analyses of differentially methylated regions
Differentially methylated regions (DMRs) were identified by using 2
methods: comb-p29 and DMRcate.30 To correct for multiple comparisons,
comb-p uses a 1-step Sidak correction,29 and DMRcate uses an FDR correc-
tion.30 Each method requires the input of parameters to be used in selecting
the regions. DMRcate30 has default values for the minimum number of CpGs
in a region (ie, 2) and a minimum length of 1000 nucleotides; we used these
values in comb-p tomaximize comparability. To be conservative,we set the sig-
nificance threshold at .01 rather than .05 and only considered a DMR to be sta-
tistically significant if it met this threshold in both packages (Sidak-corrected
P < .01 from comb-p and FDR < 0.01 from DMRcate). DMRcate annotates
DMRs to UCSC RefGene from the Illumina annotation file.Functional follow-up of significant DNA
methylation findings
Correlation of differentially methylated sites with
expression of nearby genes. To examine whether differentially
methylated sites affect gene expression, we analyzed paired methylation and
gene expression data, both of whichweremeasured in blood, from several data
sets (see this article’s Online Repository at www.jacionline.org)31-37: 2 with
methylation and gene expression in newborns (Gene Expression Omnibus
TABLE I. Sample sizes by cohort for epigenome-wide
association analyses of asthma in relation to DNAmethylation
in newborns or children
Age group Cohort No. No. of cases
Newborns ALSPAC 688 88
CHS 229 39
EDEN 150 34
Generation R 661 37
GOYA 507 37
MoBa1 666 149
MoBa2 458 239
NEST 213 45
Meta-analysis 3572 668
Children BAMSE EpiGene 307 93
BAMSE MeDALL 214 47
CHOP 382 19
GALA II 193 106
ICAC 187 92
NFBC 1986 413 17
PIAMA 197 15
Raine study 509 105
STOPPA 460 137
Meta-analysis 2862 631
Cohort-specific information on covariates is provided in Table E1.
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[IoW], n5 157),32-34 1 with newborn methylation and gene expression at age
4 years (Infancia y Medio Ambiente [INMA], n 5 113),35 another with gene
expression and methylation both measured at age 4 years (INMA, n5 112),35
1 with both measured at age 16 years (BAMSE; n 5 248),38 and the largest
with both measured in adults (BIOS consortium, n 5 3096).36,37 For each
of our significant CpGs, we examined the association with expression of tran-
scripts within a 500-kb window (6250 kb from the CpG). For DMRs, we used
a window 250 kb upstream and downstream of the end and start site of each
region. A given CpG or region might have more than 1 gene transcript in
this window. In the smaller data sets of paired gene expression andmethylation
in newborns or children, we report nominal evidence for significance
(P < .05); for the much larger adult data set, we report associations based
on FDRs of less than 0.05.
Functional annotation. To identify tissue- or cell type–specific
signals in significant EWAS results, we used eFORGE.39 Pathway and
network analyses were conducted by using Ingenuity Pathway Analysis
(Qiagen, Venlo, The Netherlands; https://www.qiagenbioinformatics.com/
products/ingenuity-pathway-analysis).40 Because of possible uncertainty
regarding genome annotation of probes flagged in the literature as potentially
cross-reactive,41 we excluded those from pathway analyses. We also
compared our methylation findings with those from published studies of
methylation in relation to asthma and evaluated whether the implicated genes
overlap with loci identified in GWASs.42,43 Additionally, we matched the
genes to which our asthma-associated CpGs and DMRs annotated against
the ChEMBL database (version 22.1) to identify whether any are targets of
approved drugs or drugs in development.44Look-up replication of significant DNA methylation
findings in nasal respiratory epithelium and
eosinophils
We examined the cell-type specificity of significant findings in whole blood
in childhood by doing a look-up in 2 data sets, withmethylationmeasuredwith
the Illumina450K in respiratory epithelium collected by means of nasal
brushing (455 sixteen-year-old Dutch children [37 with asthma] from the
PIAMA study13 and 72 African-American children [36 asthmatic patients and
38 nonasthmatic subjects],45 as well as a study with methylation measured
with the Illumina450K in eosinophils isolated from blood [16 asthmaticpatients and 8 nonasthmatic subjects aged 2-56 years from the Saguenay-
Lac-Saint-Jean [SLSJ] region in Canada).13,46,47RESULTS
Prospective analysis of newborn methylation in relation to
asthma development included 8 cohorts; the cross-sectional
analysis of methylation in children in relation to asthma included
9 cohorts, with mean ages at assessment of both asthma status and
methylation ranging from 7 to 17 years (Table I contains counts
by cohort and Table E1 in this article’s Online Repository at
www.jacionline.org contains descriptive statistics). Because
newborn DNA methylation is measured at birth, age at asthma
assessment is the time between assessment of methylation and
asthma status in prospective analyses. All models included cova-
riates and cell type, unless otherwise noted. Some studies over-
sampled asthmatic patients within their population-based
cohorts using a nested case-control or case-cohort design for
methylation measurement, and therefore the case/control ratio
varies across studies.Asthma in relation to newborn DNA methylation
Meta-analysis of asthma and newborn methylation (668 cases
and 2904 noncases; 8 cohorts: ALSPAC, CHS, EDEN, Genera-
tion R, GOYA, MoBA1, MoBa2, and NEST) identified 9 statis-
tically significant (FDR < 0.05) individual CpGs (Manhattan and
volcano plots in Fig 1). The 9 CpGs include 2 that have appeared
on a list of poorly hybridizing probes41 and thus must be regarded
with caution (ch.11.109687686R and ch.6.1218502R). The other
7 CpGs annotated to the following genes: CLNS1A, MAML2/
Mir_548, GPATCH2/SPATA17, SCOC/LOC100129858,
AK091866, SUB1, andWDR20 (Table II).We identified 35 signif-
icant DMRs (Table III and see Table E2 in this article’s Online Re-
pository at www.jacionline.org for individual CpGs within
DMRs); DMRs did not overlap the significant CpGs. Seven of
the 9 significant CpGs showed greater methylation in children
with asthma than in noncases. All 9 CpGs had P values of
3.55 3 1023 or less in a crude model and P values of
4.16 3 1024 or less in the covariate-adjusted models that did
not include cell type (see Table E3 in this article’s Online Repos-
itory at www.jacionline.org). None of the 9 CpGs had been previ-
ously reported in the literature (see Table E4 in this article’s
Online Repository at www.jacionline.org).
Forest plots showing cohort-specific odds ratios and 95% CIs
for the 9 CpGs are shown in Fig E1 in this article’s Online Repos-
itory at www.jacionline.org. Two cohorts in the newborn analysis
include subjects of non-European ancestry (NESTand CHS), and
therefore we evaluated whether these were influential. The forest
plots (Fig E1) suggest that for just 1 of the 9 CpGs (cg07156990),
the size of the effect estimate was larger in NEST than in other
studies, but the P value for heterogeneity was not close to statis-
tically significant (Pheterogeneity5 .26), and after removing NEST,
the meta-analysis P value was attenuated only slightly to
2.8 3 1026 from 9.5 3 1027. When we repeated the meta-
analysis removing both NESTand CHS, results were very consis-
tent with those from all cohorts (correlation of regression
coefficients 5 0.996). With respect to tests of heterogeneity,
only 1 of the 9 CpGs, cg13289553, produced a P value for hetero-
geneity that was even nominally significant (Pheterogeneity 5 .04,
Table E3 includes Pheterogeneity values for all 9 CpGs and the
FIG 1. Meta-analysis of asthma in relation to newborn methylation: A,Manhattan plot; B, volcano plot. The
model is adjusted for covariates and cell types.
TABLE II. Nine significant CpGs (FDR < 0.05) from the meta-analysis of asthma in relation to newborn methylation
CpG* chromosome:position
UCSC
RefGene name
UCSC
Known Geney
Average
methylation ORz (CI) P value Direction§
cg21486411 Chr 11:77348243 CLNS1A CLNS1A 0.089 1.13 (1.08-1.18) 3.43E-07 1?111111
cg16792002 Chr 11:95788886 MAML2 Mir_548 0.840 0.95 (0.93-0.97) 5.59E-07 22222221
ch.11.109687686R Chr 11:110182476 0.085 1.08 (1.05-1.11) 7.06E-07 1??11111
cg13427149 Chr 1:217804379 GPATCH2;
SPATA17
GPATCH2 0.063 1.19 (1.11-1.27) 8.04E-07 11111111
cg17333211 Chr 4:141294016 SCOC LOC100129858 0.074 1.13 (1.08-1.19) 8.25E-07 21211111
cg02331902 Chr 5:90610303 AK091866 0.089 1.12 (1.07-1.18) 8.37E-07 22111111
cg13289553 Chr 5:32585524 SUB1 SUB1 0.085 1.14 (1.08-1.20) 8.68E-07 11111112
ch.6.1218502R Chr 6:51250028 0.054 1.27 (1.15-1.39) 9.32E-07 1??11111
cg07156990 Chr 14:102685678 WDR20 WDR20 0.930 0.87 (0.83-0.92) 9.54E-07 21122222
OR, Odds ratio.
*ch probes (ch.11.109687686R and ch.6.1218502R) have been reported to be cross-hybridizing, and thus UCSC Known Gene is intentionally left blank.
Annotation based on UCSC Known Gene also fills in the nearest gene within 10 MB.
Odds ratio of having asthma for a 1% absolute increase in methylation. Adjusted for covariates and cell type.
§For each cohort participating in the analysis, 1 indicates a positive direction of effect, 2 indicates a negative direction of effect, and ? indicates missing information for that CpG
in a given cohort. Cohort order is as follows: ALSPAC, CHS, EDEN, Generation R, GOYA, MoBa1, MoBa2, and NEST.
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the largest magnitude of association, but effect estimates were
in the same positive direction across studies (see Fig E1). Ana-
lyses leaving out 1 cohort at a time do not suggest that any of
the results are driven by a single cohort (plots of untransformed
effect estimates and 95% CIs are shown in Fig E2 in this article’s
Online Repository at www.jacionline.org).Asthma in relation to childhood DNA methylation
In a meta-analysis of asthma in relation to DNA methylation
measured in childhood (631 cases and 2231 noncases; 9 cohorts:
BAMSE EpiGene, BAMSE MeDALL, CHOP, GALA II, ICAC,
NFBC, PIAMA, Raine study, and STOPPA), we identified 179
CpGs at genome-wide significance (FDR < 0.05, Manhattan andvolcano plots in Fig 2; results for all 179 CpGs are shown in Table
E5 in this article’s Online Repository at www.jacionline.org).
Nearly all (173/179) showed decreased methylation in asthma
cases versus noncases; similar predominant directionality was
seen in a recent study.13
As in the newborn analysis, results were consistent across
studies for the 179 significant CpGs (forest plots are shown in Fig
E3 in this article’s Online Repository at www.jacionline.org, and
plots of regression coefficients and 95% CIs from analyses leav-
ing one cohort out at a time are shown in Fig E4 in this article’s
Online Repository at www.jacionline.org). Two of the cohorts
were adolescents (NFBC: mean age, 16.0 years; SD, 0.4 years;
Raine study: mean age, 17.0 years; SD, 0.2 years); repeating
the meta-analysis without these 2 cohorts provided high correla-
tions with values for our FDR-significant findings from all cohorts
TABLE III. DMRs (n 5 35) for asthma in relation to newborn methylation identified by using both comb-p (P < .01) and DMRcate
(FDR < 0.01) methods
chromosome:position Gene name* No. of CpGs in region P value from comb-py FDR from DMRcatez
Chr 1: 59280290-59280842 LINC01135 5 1.23E-03 1.01E-03
Chr 1: 220263017-220263699 BPNT1; RNU5F-1 11 4.49E-04 7.74E-05
Chr 1: 1296093-1296489 MXRA8 2 9.83E-03 3.86E-04
Chr 2: 202097062-202097608 CASP8 5 1.14E-03 1.64E-05
Chr 2: 235004843-235005012 SPP2 2 6.22E-03 1.15E-03
Chr 3: 194188646-194189444 ATP13A3 3 1.06E-03 7.14E-04
Chr 4: 113218385-113218525 ALPK1 3 2.00E-03 3.69E-04
Chr 5: 158526108-158526694 EBF1 6 9.56E-04 2.16E-05
Chr 5: 81573780-81574461 RPS23 11 3.75E-03 1.47E-04
Chr 5: 64777678-64778186 ADAMTS6 10 7.09E-03 9.97E-05
Chr 6: 291687-292824 DUSP22 9 6.69E-06 1.18E-05
Chr 6: 32799997-32801050 TAP2 13 1.27E-03 6.66E-05
Chr 6: 26234819-26235610 HIST1H1D 9 6.12E-03 7.67E-05
Chr 6: 29648161-29649085 ZFP57 22 1.82E-08 3.13E-11
Chr 6: 31055396-31055503 C6orf15 5 3.61E-04 7.05E-05
Chr 7: 106694832-106695007 PRKAR2B 2 6.86E-03 7.92E-04
Chr 7: 87974722-87975316 STEAP4 4 2.32E-03 7.44E-05
Chr 7: 158045980-158046359 PTPRN2 6 1.98E-03 5.94E-04
Chr 8: 127889010-127889296 PCAT1 4 2.68E-05 1.44E-05
Chr 8: 33370172-33371226 TTI2 9 1.08E-04 6.40E-06
Chr 10: 71871364-71871634 H2AFY2 4 8.06E-03 6.19E-04
Chr 10: 65028929-65029169 JMJD1C 5 8.56E-03 6.12E-04
Chr 11: 268923-269469 NLRP6 5 3.71E-03 1.42E-03
Chr 11: 107328442-107328915 CWF19L2 10 5.10E-03 2.13E-05
Chr 12: 74931289-74932008 ATXN7L3B 10 1.03E-03 2.81E-06
Chr 12: 58329764-58330116 LOC100506844 5 1.58E-03 5.22E-04
Chr 13: 108953659-108954055 TNFSF13B 2 5.19E-03 2.37E-03
Chr 13: 31618695-31618744 TEX26 2 4.63E-03 2.09E-04
Chr 14: 69341139-69341739 ACTN1 4 1.36E-03 9.96E-04
Chr 16: 20774873-20775353 ACSM3 5 3.47E-03 1.58E-03
Chr 17: 74667833-74668253 LOC105274304 6 2.13E-03 8.34E-07
Chr 17: 21029189-21029296 DHRS7B 2 7.18E-03 5.11E-05
Chr 18: 47813745-47815431 CXXC1 10 2.58E-05 1.68E-03
Chr 21: 36421467-36421956 RUNX1 6 2.23E-03 1.67E-04
Chr 22: 24372913-24374013 LOC391322 12 3.21E-04 1.35E-07
*DMRcate annotates to UCSC RefGene from the Illumina annotation file.
Comb-p uses a 1-step Sidak multiple-testing correction on the regional P value assigned by using the Stouffer-Liptak method.
DMRcate takes the minimum Benjamini-Hochberg FDR-corrected P value in the region as representative after recalculating P values by using Gaussian kernel smoothing.
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GALA) included subjects who were not of European ancestry,
we compared significant results with and without including these
2 studies and found them to be very similar (correlation
of coefficients5 0.99). Table E5 providesP values for heterogeneity
and, where those are even nominally significant (Pheterogeneity < .05),
random-effects meta-analysis results.
Of the 179 FDR-significant CpGs, 34 CpGswere not singletons
(ie, >1 significant CpG annotated to a given gene). These 34
nonsingleton CpGs correspond to 13 genes: ACOT7,
LOC100189589, IL5RA, SLC25A26/LRIG1, RPS6KA2, KCNH2,
ZNF862/BC045757, AK096249, PRG2, EVL/AX747103,
KIAA0182, ZFPM1, and EPX (Table IV). We identified 36 signif-
icant DMRs by using both calling methods (Table V). Of the 179
FDR-significant CpGs, 31 fell within one of these 36 DMRs, and
21 of the 36 DMRs contained at least 1 FDR-significant CpG.
Three studies in our meta-analysis of asthma in relation to
childhood methylation (PIAMA, BAMSE MeDALL, and
BAMSE Epigene) also contributed to a recent meta-analysis of
both preschool and school-aged asthma outcomes13; these studies
contributed only a quarter (n5 155) of the 636 cases in our meta-analysis. That EWAS meta-analysis of asthma at preschool and
school age13 identified 14 CpGs at genome-wide significance; 7
were among our 179 genome-wide significant findings for child-
hood methylation (cg13835688, cg14011077, cg03131767,
cg13628444, cg10142874, cg01901579, and cg01445399), and
6 others represented in our data set (cg15344640, cg11456013,
cg01770400, cg19764973, cg08085199, and cg16592897) were
nominally statistically significant (P <.05) and direction matched
for all 13. When repeating the meta-analysis excluding those 3
studies, 13 of the 14 CpGs had P values of less than .05 and direc-
tions of association matched; only cg06483820 produced no evi-
dence for association (P5 .74). In additional comparison with the
literature, differential methylation in ACOT7 and ZFPM1 was
previously identified in an EWAS of blood in relation to IgE48
and in 2 of our contributing studies, ICAC and ALSPAC, to
asthma,10,12 as well as in an EWAS of nasal epithelium to
asthma.45
Comparing newborn and childhood methylation models, none
of the 9 FDR-significant CpGs for newborn methylation were
nominally significant (P <.05) in the childhood methylation anal-
ysis. Only 6 of the 179 CpGs significant for asthma in relation to
FIG 2. Meta-analysis of asthma in relation to childhoodmethylation: A,Manhattan plot; B, volcano plot. The
model is adjusted for covariates and cell types. CpGs corresponding to more than 1 gene with significant
CpGs (FDR < 0.05) are highlighted in red.
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newborn methylation; 2 of these had consistent directions of ef-
fect (cg16409452 [EVL] and cg09423651 [NCK1]).Replication of findings for asthma in relation to
childhood methylation in nasal epithelium
We assessed whether the 179 CpGs differentially methylated in
blood in relation to asthma in childhood were also differentially
methylated in relation to current asthma in nasal epithelium from
2 studies (see Table E6 in this article’s Online Repository at www.
jacionline.org). Among 455 Dutch children (37 with asthma)
studied at age 16 years,13 we found evidence for replication for
20 CpGs, matching direction-of-effect estimates and nominal sig-
nificance (P <.05). Among African American children aged 10 to
12 years with persistent asthma plus atopy (36 cases) compared
with 36 nonasthmatic nonatopic children, 128 of the 179 CpGs
produced effect estimates for asthma in the same direction and
also had P values of less than .05 for association.Replication of findings for asthma in relation to
childhood methylation in eosinophils
We looked up the 179 CpGs differentially methylated in
childhood in relation to asthma in EWASs of 16 asthma cases
and 8 noncases inwhommethylation had beenmeasured in purified
eosinophils. Of the 177CpGs included in this data set, all directions
of association with asthma were the same as in the PACE
consortium and 148 produced P values of less than .05 (see
Table E7 in this article’s OnlineRepository atwww.jacionline.org).Functional annotation
For the newborn analysis, among the 7 significant CpGs (after
removing the 2 ‘‘ch’’-probes), all 7 were near a transcriptionfactor binding site, and 6 were in a DNase hypersensitivity site
identified in at least 1 ENCODE cell line, supporting a potential
functional relevance to transcriptional activity (see Fig E5 in this
article’s Online Repository at www.jacionline.org).
Among the 179 CpGs significantly differentially methylated in
childhood in relation to asthma, there was significant depletion of
localization to CpG islands (17 CpGs, 9.5%, P 5 1.09 3 10211)
and promoters (34 CpGs, 19.0%, P 5 1.10 3 1024). Functional
annotation plots are shown in Fig E6 in this article’s Online Re-
pository at www.jacionline.org for the 13 gene regions to which
the 34 nonsingleton CpGs annotate. Among the 179 CpGs, 113
were in DNAse hypersensitivity sites. Using eFORGE39 to
examine enrichment of all 179 significant CpGs for histonemarks
(H3K27me3, H3K36me3, H3K4me3, H3K9me3, and
H3K4me1), we found significant enrichment for H3K4me1 in
blood and lung tissue and H3K36me3 in blood (see Fig E7 in
this article’s Online Repository at www.jacionline.org).Association of methylation and gene expression
For the CpGs and regions we identified as differentially
methylated in either newborns or children in relation to asthma,
we assessed association between paired levels of blood DNA
methylation and whole-blood gene expression for nearby tran-
scripts defined as within a 500-kb window of the significant CpG
or DMR in newborns (Gene Expression Omnibus, n5 38; INMA,
n5 113; IoW, n5 157), children (4-year-olds in INMA, n5 112;
16-year-olds in BAMSE, n5 248), and adults (BIOS consortium,
n 5 3096).
Among 9 CpGs differentially methylated in newborns in
relation to asthma, 3 were associated with expression of a nearby
transcript in 3 data sets (cg17333211 in newborns, 4-year-olds,
and adults and cg02331902 and cg07156990 in 2 newborn data
sets and 4-year-olds), and an additional 3 CpGs were associated
with expression in 2 data sets (cg13427149 in 16-year-olds and
TABLE IV. Thirty-four CpGs annotated to 13 genes with more than 1 significant CpG (FDR < 0.05) from the meta-analysis of
asthma in relation to childhood methylation
CpG chromosome:position
UCSC
RefGene name
UCSC
Known gene* P value
Average
methylation ORy (CI) Directionz
cg13066938 Chr 1: 6341140 ACOT7 ACOT7 1.67E-05 0.682 0.91 (0.88-0.95) 221?22122
cg21220721 Chr 1: 6341230 ACOT7 ACOT7 1.02E-08 0.763 0.94 (0.92-0.96) 221222222
cg09249800 Chr 1: 6341287 ACOT7 ACOT7 1.19E-08 0.916 0.88 (0.84-0.92) ???222?22
cg11699125 Chr 1: 6341327 ACOT7 ACOT8 7.54E-10 0.799 0.90 (0.87-0.93) 221222222
cg00043800 Chr 2: 74612144 LOC100189589 LOC100189589 1.32E-05 0.585 0.91 (0.87-0.95) 222221122
cg17988187 Chr 2: 74612222 LOC100189589 LOC100189590 1.21E-06 0.699 0.90 (0.86-0.94) 221?22122
cg01310029 Chr 3: 3152374 IL5RA IL5RA 4.18E-06 0.744 0.89 (0.85-0.94) 222?22122
cg10159529 Chr 3: 3152530 IL5RA IL5RA 4.48E-06 0.736 0.90 (0.86-0.94) 222?2222
cg07410597 Chr 3: 66404129 SLC25A26 LRIG1 2.70E-07 0.773 0.88 (0.84-0.93) 221222122
cg04217850 Chr 3: 66428294 SLC25A26 LRIG2 2.35E-06 0.747 0.88 (0.83-0.93) 221222222
cg15304012 Chr 6: 166876490 RPS6KA2 RPS6KA2 1.86E-05 0.697 1.08 (1.04-1.13) 111111111
cg19851574 Chr 6: 167178233 RPS6KA2 RPS6KA2 3.42E-06 0.671 0.95 (0.94-0.97) 221222222
cg03329755 Chr 6: 167189272 RPS6KA2 RPS6KA2 6.14E-06 0.818 0.91 (0.88-0.95) 211222222
cg05184016 Chr 7: 149543136 ZNF862 BC045757 2.74E-08 0.817 0.85 (0.80-0.90) 221222222
cg07970948 Chr 7: 149543165 ZNF862 BC045757 6.39E-08 0.771 0.91 (0.88-0.94) 222122122
cg06558622 Chr 7: 149543177 ZNF862 BC045757 3.39E-09 0.818 0.88 (0.85-0.92) 222222222
cg24576940 Chr 7: 150648283 KCNH2 KCNH2 1.83E-05 0.848 0.87 (0.81-0.93) 222222222
cg23147443 Chr 7: 150649655 KCNH2 KCNH2 1.83E-06 0.842 0.89 (0.85-0.93) ???222?22
cg18666454 Chr 7: 150651937 KCNH2 KCNH2 1.46E-07 0.761 0.89 (0.86-0.93) 222222222
cg13850063 Chr 9: 138362321 AK096249 5.49E-08 0.819 0.78 (0.71-0.85) 221?22222
cg14011077 Chr 9: 138362327 AK096249 7.02E-09 0.797 0.86 (0.82-0.90) 222?22222
cg15700636 Chr 11: 57156050 PRG2 PRG2 2.35E-07 0.746 0.89 (0.85-0.93) 221222222
cg08773180 Chr 11: 57157607 PRG2 PRG2 1.77E-07 0.741 0.89 (0.85-0.93) 221222122
cg12819873 Chr 11: 57157632 PRG2 PRG2 9.55E-06 0.760 0.90 (0.86-0.94) 222222122
cg16409452 Chr 14: 100610186 EVL AX747103 4.89E-07 0.770 0.91 (0.87-0.94) 221222222
cg14084609 Chr 14: 100610407 EVL AX747103 2.96E-09 0.780 0.89 (0.85-0.92) 222222222
cg18550847 Chr 14: 100610570 EVL AX747103 7.10E-07 0.730 0.91 (0.88-0.94) 221?22222
cg08640475 Chr 16: 85551478 KIAA0182 2.36E-06 0.815 0.92 (0.89-0.95) 221222222
cg10099827 Chr 16: 85551514 KIAA0182 1.32E-06 0.808 0.92 (0.89-0.95) 222222222
cg08940169 Chr 16: 88540241 ZFPM1 ZFPM1 2.93E-07 0.778 0.91 (0.87-0.94) 222222122
cg04983687 Chr 16: 88558223 ZFPM1 ZFPM1 1.33E-10 0.744 0.93 (0.90-0.95) 222222222
cg25173129 Chr 17: 56269410 EPX EPX 8.09E-07 0.753 0.88 (0.84-0.93) 221222122
cg02970679 Chr 17: 56269818 EPX EPX 9.99E-07 0.776 0.88 (0.83-0.92) 222222122
cg17374802 Chr 17: 56270828 EPX EPX 2.06E-06 0.713 0.90 (0.86-0.94) 222?22122
OR, Odds ratio.
*Annotation based on UCSC Known Gene also fills in nearest gene within 10 MB.
Odds ratio of having asthma for a 1% absolute increase in methylation. Adjusted for covariates and cell type.
For each cohort, 1 indicates a positive direction of effect, 2 indicates a negative direction of effect, and ? indicates missing information for that CpG. Cohort order is as follows:
BAMSE EpiGene, BAMSE MeDALL, CHOP, GALAII, ICAC, NFBC1986, PIAMA, RAINE, and STOPPA.
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4-year-olds; see Table E8, A, in this article’s Online Repository
at www.jacionline.org). All regions differentially methylated in
newborns in relation to asthma were related to expression in at
least 1 data set (see Table E8, B).
For methylation in childhood, nearly all (176/179) CpGs
related to asthma also associated with expression in at least 1
data set (Table E8, C). CpGs annotated to IL5RA were
significantly associated with expression in 4 cohorts (BIOS con-
sortium, INMA, IoW, and BAMSE). All 36 regions differentially
methylated in childhood were associated with expression of a
nearby transcript in at least 1 data set (see Table E8, D).Pathway analysis
Using Ingenuity Pathway Analysis, we identified pathways, as
well as disease processes and biological functions, significantly
enriched (P < .05) for the genes to which significant individualCpGs or DMRs annotated in the meta-analysis of asthma in rela-
tion to newborn or childhood methylation (see Tables E9 and E10
in this article’s Online Repository at www.jacionline.org). Genes
towhich the 7 significant CpGs (after removing ‘‘ch’’-probes) and
35 significant DMRs in newborn methylation analysis were anno-
tated were significantly enriched (P <.05) for canonical pathways
relevant to immune function in asthmatic patients, including
endothelial nitric oxide synthase (eNOS) signaling, the inflamma-
some, and nuclear factor kB (NF-kB) signaling (see Table E9).
Enriched disease processes and biologic functions included
several involving immune function and others involving immune
and organ development (see Table E9). Given the larger number
of implicated genes for childhood methylation, many more path-
ways, disease processes, and biological functions were enriched
(see Table E10). There was substantial overlap in newborns and
children in the significantly enriched pathways and diseases and
biological function relevant to immune function, immunologic
disease, and development (see Fig E8 in this article’s Online
TABLE V. DMRs for asthma in relation to childhood methylation with adjustment for covariates and cell type identified by using
both comb-p (P < .01) and DMRcate (FDR < 0.01) methods
chromosome:position Gene name*
No. of CpGs
in region
P value from
comb-py
FDR from
DMRcatez
Chr 1: 161575716-161576323 HSPA7 4 8.61E-03 1.24E-03
Chr 1: 209979111-209979780 IRF6 13 4.62E-04 1.90E-04
Chr 1: 2036283-2036644 PRKCZ 4 2.00E-04 3.14E-05
Chr 1: 87596820-87596935 LINC01140 3 1.58E-03 2.79E-05
Chr 2: 149639612-149640260 KIF5C 4 3.50E-03 1.14E-05
Chr 2: 11917490-11917788 LPIN1 3 4.81E-03 6.25E-04
Chr 3: 195974258-195974330 PCYT1A 3 5.07E-05 2.00E-05
Chr 3: 3151795-3152917 IL5RA 6 1.35E-08 2.12E-09
Chr 5: 38445220-38446193 EGFLAM 9 5.11E-06 1.28E-05
Chr 5: 132008525-132009631 IL4 4 5.36E-07 3.11E-05
Chr 6: 112688010-112688931 RFPL4B 4 4.89E-05 5.19E-04
Chr 6: 166876490-166877039 RPS6KA2;RPS6KA2-IT1 8 3.08E-05 1.74E-06
Chr 7: 156735383-156735657 NOM1 3 7.11E-03 2.82E-03
Chr 7: 149543136-149543178 ZNF862 3 3.85E-16 1.43E-16
Chr 7: 65419185-65419289 VKORC1L1 7 2.82E-03 1.04E-03
Chr 8: 832917-833049 ERICH1-AS1;DLGAP2 3 6.15E-03 6.44E-03
Chr 8: 141046436-141046853 TRAPPC9 5 8.93E-07 3.45E-09
Chr 9: 138362321-138362505 PPP1R26-AS1 3 2.72E-05 1.44E-09
Chr 9: 130859454-130859607 SLC25A25 2 2.69E-08 5.84E-08
Chr 11: 65545808-65547173 AP5B1 8 1.31E-10 9.73E-12
Chr 11: 69291998-69292065 LINC01488 3 4.55E-04 1.65E-04
Chr 11: 59856225-59856359 MS4A2 2 1.50E-03 3.25E-04
Chr 12: 15125458-15126021 PDE6H 4 6.93E-03 7.65E-06
Chr 14: 100610071-100610668 EVL 6 7.79E-16 1.24E-19
Chr 15: 64275810-64275854 DAPK2 2 4.91E-04 2.04E-04
Chr 15: 99443213-99443667 IGF1R 4 6.57E-05 2.41E-04
Chr 16: 875257-875627 PRR25 4 3.34E-03 3.21E-03
Chr 16: 88539861-88540397 ZFPM1 5 1.09E-04 1.13E-05
Chr 16: 615709-616221 PRR35 5 1.62E-04 2.70E-07
Chr 16: 85551478-85551749 GSE1 3 5.27E-07 2.37E-07
Chr 17: 56269410-56270829 EPX 5 6.20E-11 1.41E-08
Chr 17: 78682785-78683458 RPTOR 5 1.18E-04 4.03E-04
Chr 19: 51961666-51961938 SIGLEC8 3 2.37E-04 5.07E-04
Chr 19: 50553682-50554511 LOC400710 10 1.78E-07 3.81E-06
Chr 20: 35503832-35504554 TLDC2 8 1.23E-03 5.90E-08
Chr 21: 42520365-42520903 LINC00323 3 1.41E-04 2.64E-05
*DMRcate annotates to UCSC RefGene from Illumina annotation file. The first listed gene is shown.
Comb-p uses a 1-step Sidak multiple-testing correction on the regional P value assigned by using the Stouffer-Liptak method.
DMRcate takes the minimum Benjamini-Hochberg FDR-corrected P value in the region as representative after recalculating P values by using Gaussian kernel smoothing.
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the network of 4 overlapping disease and biological processes be-
tween newborns and children: tissue morphology, immunological
disease, inflammatory disease, and cell-mediated immune
response.Druggable targets
Among regions differentially methylated in newborns in
relation to later asthma, RUNX1 is a target of the agent
CHEMBL2093862 andCASP8 is the target of CHEMBL2105721
(Nivocasan), an inhibitor of this caspase and 2 others (1 and 9).
Among genes with individual CpGs significantly differentially
methylated in childhood in relation to asthma, KCNH2 (3 signif-
icant CpGs) is a target of several approved drugs with mechanism
of action of blockingHERG (humanEther-a-go-go-related gene),
including the antiarrhythmic agents amiodarone hydrochloride,
dofetilide, and sotalol. Notably, sotalol is also a b-adrenergic re-
ceptor antagonist. IL5RA (2 significant CpGs) is the target for a
drug approved for use in patients with severe asthma,benralizumab, the mechanism of action of which is antagonism
of this gene.49 Several other genes implicated by either an individ-
ual CpG (16 genes) or DMR analysis (5 genes, including IGF1R)
are targets for approved or potential drugs (see Tables E11 and
E12 in this article’s Online Repository at www.jacionline.org).DISCUSSION
This epigenome-widemeta-analysis of the association between
childhood asthma and DNA methylation measured at birth or
childhood identified numerous novel CpGs and regions differen-
tially methylated in relation to this common health outcome. The
9 CpGs and 35 regions significantly differentially methylated in
relation to asthma in newborn bloodDNA are potential markers of
risk for disease development. There were many more statistically
significant associations of asthma in relation to childhood DNA
methylation, with 179 CpGs and 36 regions; these might reflect
both the risk for and effects of this disease.50
Among the significant CpGs in newborns, 6 were in DNAse
hypersensitivity sites, supporting a potential regulatory effect on
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FIG 3. A network is shown for 4 categories of disease and biological functions overlapping between
analyses of asthma in relation to either newborn or childhood methylation: immunological disease, cell-
mediated immune response, inflammatory disease, and tissue morphology. A gene is connected to a
disease or function if it has been previously shown to be involved in it. All genes marked in red are
implicated from newborn methylation analyses, and those marked in in orange are implicated from
childhood methylation analyses.
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(GPATCH2/SPATA17) and cg16792002 (MAML2) annotate
have previously been associated with obesity phenotypes,51,52
conditions related to childhood asthma. This supports the poten-
tial functional importance and asthma relevance of our newborn
findings.
Some CpGs on the 450K array have been reported as
potentially polymorphic by virtue of location near SNPs.41 Given
that many of the nearby SNPs are low frequency andmost will not
interfere with probe binding, which would generate a truly
spurious result rather than filter these in advance; in the PACE
consortium we examined statistically significant CpGs post hocfor occurrence on lists of potentially problematic CpGs in the
literature, as recently recommended by others.17,18 Lists of poten-
tially problematic probes change over time, as do underlying gene
annotations.53We note that 2 of the 9 significant CpGs in newborn
methylation (ch.11.109687686R and ch.6.1218502R) were
flagged as potentially nonspecific (‘‘ch’’) probes by Chen
et al.41 We provide association results for these because they
might be useful to others but, acknowledging this caveat, do not
include them in downstream analyses that assume certainty
regarding gene localization. With respect to the issue of CpGs
previously reported as near SNPs, we visually assessed plots of
all significant CpGs in 3 of our largest cohorts (MoBa1 and
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Online Repository at www.jacionline.org] and STOPPA for child-
hood methylation [see Fig E10 in this article’s Online Repository
at www.jacionline.org]) to verify unimodal distributions.
We identified many more CpGs and DMRs associated with
later asthma, likely because these also capture disease effects. Our
findings might also reflect different pathophysiologic mecha-
nisms related to newborn versus childhood methylation and
asthma. A comprehensive search for methylation signals at birth
that predict later development of asthma likely requires much
larger sample sizes given the intervening effects of exposures and
developmental processes that may outweigh effects of small
methylation differences present at birth.54 However, although
overlap at the level of specific CpGs or DMRs was low, there
was substantial overlap at the pathway and network levels (Fig
3 and see Fig E8).
To follow-up our differentially methylated signals for potential
functional effect, we examined correlations with gene expression.
Because of the relatively small sizes of the paired gene expression
data sets in newborns or children, we also examined amuch larger
data set of adults to increase power. Although the number of
subjects in data sets of newborns or children with both gene
expression and methylation data were modest (range, 38-248),
limiting power to find correlations, we found that a high propor-
tion of CpGs and DMRs related to asthma were also correlated
with gene expression in at least 1 data set in this age range. This
further supports the functional effect of our methylation findings.
Our search for druggable targets identified 2 genes from the
newborn DMR analysis that are targets for either approved or
potential drugs. The childhood analysis identified more drug
targets. One of these genes, IL5RA, already has an approved
asthma drug that inhibits its product. This analysis further sup-
ports the relevance to asthma pathogenesis and the potential clin-
ical usefulness of these findings. Investigating the potential to
repurpose approved drugs for new indications has been recently
highlighted as a cost-effective way to develop new therapeutic
modalities.55
We meta-analyzed results across studies by using fixed-effects
meta-analysis with inverse variance weighting. Recently, Rice
et al25 have summarized issues regarding the choice of meta-
analytic models for combining study-specific results in genomic
analyses and show that the inverse variance–weighted average es-
timates a reasonable and interpretable parameter, even under the
assumption that effect sizes differ. Furthermore, they point out
that a fixed-effects meta-analysis does not require the assumption
of homogeneity. Rice et al25 also emphasize the importance of
evaluating meta-analysis effect estimates and significance tests
along with visualization of study-specific estimates rather than
relying on a single statistical estimate of heterogeneity. Accord-
ingly, we provide forest plots to show the consistency of study-
specific findings for all significant meta-analysis results (see Fig
E1 for newborn methylation and Fig E3 for childhood methyl-
ation). Furthermore, we performed a systematic leave-one-out
meta-analysis for all significant CpGs, in which we leave each
cohort out one by one (see Fig E2 for newborn methylation and
Fig E4 for childhood methylation). In addition, where there is
even nominal evidence for heterogeneity (Pheterogeneity < .05),
we provide random-effects results in Tables E3 (newborn methyl-
ation) and E5 (childhood methylation).
We recognize various limitations. As in most EWASs,13 as well
as GWAS meta-analyses,56 asthma was defined by questionnaire.As in Xu et al,13 we used a reported doctor’s diagnosis combined
with symptoms andmedication use. Although use of self-reported
outcomes can lead to misclassification, this should be nondiffer-
ential with respect to methylation and thus should lead to bias to-
ward the null rather than create false-positive findings.We did not
stratify the analyses by allergic status becausemost cohorts do not
have objective measures of atopy, and in many cohorts sample
size would have been inadequate for stratification.
We also note that the diverse cohorts included in the analysis
could have introduced heterogeneity based on ancestry or, in the
analysis of methylation in older children, 2 studies in older
adolescents. However, in the studies of older children, non-
European ancestry of older children did not appear to be
influential in sensitivity analyses. Although magnitudes of the
associations are modest, this is consistent with other genome-
wide analyses of methylation in newborns and children in relation
to various exposures.15,57,58 These effect sizes are not surprising
given that highly reproducible genetic signals discovered in
asthma GWASs, such as ORMDL3,59 are also modest.
We used logistic regression in the prospective analyses of
newborn methylation in relation to asthma rather than Cox
regression, which is not commonly used in high-dimensional
genomic studies. If time to asthma were available or could be
estimated reliably, a Cox model would be more efficient. How-
ever, for asthma, the exact time to disease development is poorly
estimated. Thus epidemiologic studies generally use age at
diagnosis, but there can be a very long lag between disease onset
and diagnosis. In our scenario, where the exact time to asthma is
unknown, using error-prone outcomes can actually result in larger
bias. Thus, considering the tradeoff between bias and efficiency,
logistic regression is the better option.We also note that where the
condition under study has less than 10% prevalence, as is the case
for our outcome of asthma diagnosed at school age, the odds ratio
is a good approximation of the hazard ratio.60 To address the
important aspect of age at diagnosis of asthma, we used age at
diagnosis for the harmonized definition of asthma. With the
exception of a couple of studies, in which sensitivity analyses
removing them did not suggest undue influence, the range of
mean ages was not large.
Unmeasured confounding is a concern in all analyses of
observational data. With high-dimensional genomic data, vari-
ability caused by batch effects is an additional potential source of
unmeasured confounding.61 In this meta-analysis each cohort
corrected for batch effects by using methods most suitable for
their own data. In most studies methylation analyses were
completed over a short period of time, which greatly reduces
batch effects.61When using methods such as adjustment for batch
variables or ComBat, one must specify the putative batch vari-
ables. To the extent that there are unknown factors contributing
to laboratory variability, there might be residual confounding.
Various methods have been proposed to attempt to address un-
measured confounding in high-dimensional data. However, in
meta-analyses findings tend to be significant because they are
consistent across studies. Thus the chance that unmeasured con-
founding is operating in the same manner across studies done in
different countries with methylationmeasured in different labora-
tories and at different times, resulting in false-positive significant
associations in the meta-analysis, is greatly reduced. Further-
more, in the childhood methylation analysis we have substantial
replication of findings from a recently published meta-analysis,13
even after overlapping subjects are removed. In addition, the
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isolated from 2 tissues highly relevant for asthma, eosinophils and
nasal respiratory epithelium, provides compelling evidence that
our findings are not driven by unmeasured confounding.
Identification of DMRs provides a way to reduce the dimen-
sionality of the epigenome-wide methylation data and can
identify associations at the regional level, where there are not
individually significant CpGs. The 2 methods that we used for
DMR identification, DMRcate and comb-p, are the only 2
published methods available for use with results of meta-
analyses.29,30 A recent review noted that the variousmethods pub-
lished for identifying DMRs use different assumptions and
statistical approaches and thus rarely identify exactly the same re-
gions.62 Accordingly, to reduce false-positive results, we reported
only DMRs identified as statistically significant by both methods.
We measured DNA methylation in whole blood, a mix of cell
types. Cell counts were not measured, but we adjusted our models
for estimated cell counts using established reference-based
methods to address confounding by cell-type differences.21 For
childhood, as opposed to newborn, methylation, we used an adult
reference panel because a suitable one is not available for chil-
dren. Notably, the considerable overlap between our findings in
whole blood and smaller studies of 2 highly asthma-relevant tis-
sues, nasal epithelium, an excellent proxy for airway epithelium
in studies of asthma,63 and purified eosinophils, greatly reduces
the concern that our findings are false-positive results because
of failure to fully account for the influence of asthma on white
blood cell proportions.
In addition to confirmation of findings in studies of eosino-
phils and nasal respiratory epithelium and the high power
resulting from meta-analyses, other strengths of the study
include our efforts to standardize the definition of asthma
across studies, the large sample size provided by meta-analyses,
and evaluation of potential biological implications of our
findings through detailed examination of functional annotation,
pathway analysis, correlation of differentially methylated sites
with gene expression, and consideration of potential druggable
targets.
In summary, we identified numerous novel CpGs and regions
associated with childhood asthma in relation to DNAmethylation
measured either at birth in prospective analyses or in childhood in
cross-sectional analyses. Many of the genes annotated to these
CpGs and regions are significantly enriched for pathways related
to immune responses crucial in asthmatic patients; several genes
are targets for either approved or investigational drugs. Most
differentially methylated CpGs or regions correlated with expres-
sion at a nearby gene. Many more individual CpGs were
differentially methylated in childhood in relation to their current
asthma status. There was appreciable overlap with findings in
nasal respiratory epithelium and purified eosinophils. The CpGs
and regions identified in newborns might be potential biomarkers
of later asthma risk; those identified in childhood likely reflect
both processes that affect disease risk and effects of having the
disease. The novel genes implicated by this study might shed new
light on asthma pathogenesis.
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